With reference to the subject cited, this is to inform the Exchanges that the Board Meeting of Sai Parenterals Limited held on Saturday, the 23rd day of May, 2026 at 11:30 a.m. at the Registered ....
SAIPARENT · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sai Parenterals Limited held its Board Meeting on May 23, 2026, and approved unaudited standalone and consolidated financial results for Q3 FY2026 (nine months ended December 31, 2025) along with audited standalone and consolidated results for the full year ended March 31, 2026. Standalone revenue for FY2026 stood at ₹1,245.36 million with PAT of ₹167.77 million, while consolidated revenue reached ₹3,895.13 million with PAT of ₹142.59 million. The auditors from R Kabra & Co. LLP issued an unmodified opinion on the audited results. The company disclosed that it has filed a Draft Red Herring Prospectus (DRHP) for its proposed IPO and completed acquisition of a 74.64% controlling stake in Noumed Life Sciences Limited (UK) for AUD 22 million through its wholly-owned subsidiary. This is the company's first filing under SEBI listing regulations as it was not previously listed.
The clean audit opinion and strong standalone PAT growth of 63% are positive signals for potential IPO investors. The significant jump in revenue and assets reflects the recent acquisition strategy, though investors should monitor integration of the UK subsidiary.